Estimating the distribution of a novel clinical biomarker (FGF-23) in the US population using findings from a regional research registry

• Joseph A. Johnston ,

  Roles Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Writing – original draft

  * E-mail: johnstonja@lilly.com

  Affiliation Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  http://orcid.org/0000-0003-3913-9256

  ⨯
• David R. Nelson,

  Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – review & editing

  Affiliation Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Limin Zhang,

  Roles Conceptualization, Investigation, Writing – review & editing

  Affiliation Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Sarah E. Curtis,

  Roles Investigation, Writing – review & editing

  Affiliation Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• James R. Voelker,

  Roles Investigation, Writing – review & editing

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• John R. Wetterau

  Roles Conceptualization, Investigation, Writing – original draft

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯